1Karnisawa T, Funata N, Hayashi T, et al. A. clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol, 2003, 38: 982-984.
2Stone JH, Zen Y, Deshpande V. IgG4-Related Disease,N Engl J Med, 2012, 366:539-551.
3Yamamoto M, Takahashi H, Ohara M, et al. A conceptualization for Mikulicz' s disease as an IgG4-related plasmacytic disease. Mod Rheumatol, 2006, 16:335-340.
4Ebbo M, Daniel L, Pavic M, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine, 2012, 91:49-56.
5Khosrohahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Current Opinion in Rheumatology,2011,23 :57- 66.
6Hamano H, Kawa S, Horiuhi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med, 2001, 344:732-738.
7Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol, 2011, 23: 108-113.
8Sato Y, Notohara K, Kojima M, et al. IgG4-related disease: historical overview and pathology of hematological disorders. Pathol Int, 2010, 60: 247-258.
9Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease, lessons from 10 consecutive patients. Medicine, 2012, 91 : 57-66.
10StoneJH, Zen Y, Deshpande V, et at. IgG4-related disease. N EnglJ Med, 2012, 366: 539-551.
